This site is intended for health professionals only

Novel ocular hypertension drug shows promise


Bausch + Lomb, the global eye health company, and NicOx S.A. (NYSE Euronext Paris: COX) today announced positive top-line results from the Phase 2b study conducted with BOL-303259-X, a novel nitric oxide-donating prostaglandin F2-alpha analog, in patients with open-angle glaucoma or ocular hypertension.

The phase 2b study met its primary efficacy endpoint and showed positive results on a number of secondary endpoints. The primary efficacy endpoint was the reduction in mean diurnal intraocular pressure (IOP) on day 28.

BOL-303259-X (previously NCX 116) was licensed by NicOx to Bausch + Lomb in March 2010. Bausch + Lomb will pay a $10 million milestone payment to NicOx and will initiate a global Phase 3 development program for BOL-303259-X.

BOL-303259-X consistently lowered IOP in a dose-dependent manner. Two of the four doses tested showed greater IOP reduction compared with Xalatan® 0.005%, with the differences reaching more than 1mmHg (statistical significance: p<0.01).

“We know from several studies that every mmHg of IOP reduction is important, as it reduces the risk of developing glaucoma and progression of glaucoma,” said Robert N. Weinreb, M.D., Distinguished Professor and Chairman of Ophthalmology, University of California San Diego. “A safe and well-tolerated therapy that can better lower IOP compared to current prostaglandin therapies would be welcomed by both clinicians and patients.”

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

The most efficacious dose of BOL-303259-X also showed positive results on a number of secondary endpoints, including consistently better control of IOP over 24 hours on day 28 as well as a statistically significant greater percentage of responders vs. Xalatan® 0.005%, defined as patients achieving an IOP of 18mmHg or less.

The responder rate was 68.7% for the most efficacious dose of BOL-303259-X, compared to 47.5% for Xalatan® 0.005% (p=0.006).

The safety of BOL-303259-X was comparable to Xalatan®. The most common adverse event was ocular hyperaemia (red eye), which occurred at a similar rate across all treatment groups.

Bausch + Lomb initiated the randomised, investigator-masked Phase 2b study in November 2010 to identify the most efficacious and safe dose of BOL-303259-X for the reduction of IOP.

The study enrolled 413 patients across 23 sites in the United States and Europe.

Patients were randomised to receive either BOL-303259-X (various concentrations) or Xalatan® 0.005% (latanoprost) once a day in the evening for 28 days.

Bausch + Lomb

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine